David Rosenbaum
About David Rosenbaum
David Rosenbaum, PhD, is the Chief Development Officer with over 20 years of experience in developing new therapies, specializing in non-absorbed, minimally-systemic new chemical entities.
Chief Development Officer David Rosenbaum
David Rosenbaum, PhD, currently holds the position of Chief Development Officer. His extensive background in pharmacology and a focus on non-absorbed, minimally-systemic new chemical entities have played a significant role in his career development. As CDO, he leverages his expertise in drug development to lead and direct efforts in creating new therapies for global registration.
David Rosenbaum Educational Background
David Rosenbaum, PhD, has a strong educational foundation in the sciences. He earned his Ph.D. in pharmacology from Boston University School of Medicine, followed by an M.S. in toxicology from Albany Medical College. His academic journey began with a B.A. in biology from the University of Pennsylvania. These qualifications have provided him with a thorough understanding of pharmacological and toxicological principles, critical to his roles in drug development.
David Rosenbaum's Experience at Arthur D. Little (ADL)
David Rosenbaum began his career at Arthur D. Little (ADL) as a senior consultant and study director. In this role, he was responsible for offering expert consultancy and directing studies, which laid the groundwork for his future successes in the pharmaceutical industry. His early experience at ADL contributed significantly to his overall skillset in pharmacological research and development.
David Rosenbaum's Role at GelTex Pharmaceuticals
As the vice president of preclinical research and development at GelTex Pharmaceuticals, David Rosenbaum played a pivotal role in the development and approval of two non-absorbed drugs: RenaGel® and WelChol. His contribution was integral to advancing these medications through the development pipeline, reflecting his expertise in preclinical research and non-absorbed drug formulations.
David Rosenbaum's Achievements at Trine Pharmaceuticals
During his tenure as vice president of drug development at Trine Pharmaceuticals, David Rosenbaum contributed significantly to the company's objectives. His cumulative experience of over 20 years in developing new therapies for global registration positions him as a key player in the pharmaceutical sector. He has successfully filed numerous Investigational New Drug (IND) applications and achieved two approved New Drug Applications (NDAs), underscoring his impact on drug development initiatives.